Innovative Blutzuckermessung mit Trendwarnfunktion: Kosteneffektivität und Budgetauswirkung bei insulinbehandelten Diabetikern in Deutschland

Autori: Wentzell N, Krumreich J, Schauf M, Zöllner YF


Hypoglycaemic events (HEs) are severe acute complications in patients with diabetes mellitus, especially in insulin-treated diabetics, and cause high treatment costs. OneTouch Verio and OneTouch Verio IQ (OTV) use the so called PatternAlertTM technology (PAT) which logs and analyses measurements, and informs the patient about a potential HE.


To identify how many HEs can be avoided by using OTV compared to a conventional self-monitoring of blood glucose (cSMBG) device, at which costs, and with what impact on overall treatment costs.

Materials and methods

Cost-effectiveness analysis and budget-impact analysis applied to insulin treated diabetics in Germany.


The use of OTV, in the base-case scenario (incidence of HEs 8.99 %, sensitivity of PAT 19 %, alert adherence 84 %), leads to an extra 0.014 avoided HEs per patient per year, in comparison to a cSMBG device. At the same price of test strips for both devices, this implies cost savings of approximately 8.31 € per patient per year and about 579.85 € saved per HE avoided. In Germany, with a population of 2,026,490 insulin-treated diabetics (prevalence 7.3 %), 29,059 HEs could thus be avoided. This results in potential total cost savings of 16,849,475 € per year.


This model considers only the direct costs of HEs and their treatment costs. Potentially avoided indirect costs (productivity losses) or intangible costs (through distress and suffering) are not included (conservative approach). For the calculation of cost-effectiveness and budget impact, full implementation of OTV is assumed.


The PAT feature could avoid a high number of HEs and may lead to considerable cost-savings if implemented widely in the target population.


hypoglycaemia, PatternAlertTM-Technology, cost-effectiveness, diabetes, budget-impact.


Visualizzazioni Totali: 18